When it comes to domestic generic drugs, many people may instinctively associate them with stereotypes such as âcheap substitutes,â âsecond-choice options,â or âcompromised efficacy.â However, Saibeixin Pazopanib Tablets stand as a clear example that challengesâŠ
For many patients with advanced renal cell carcinoma, breast cancer, or neuroendocrine tumors, targeted therapy represents a critical source of hopeâhelping to extend survival and control disease progression. đ° Yet before that hope can beâŠ
On March 8, 2023, China’s National Medical Products Administration (NMPA) announced a significant glumetinib approvalâthe conditional market authorization of the Class 1 innovative drug Glumetinib Tablets (brand name: Hai Yi TanÂź), developed by Shanghai HaiHe Pharmaceutical.âŠ
Nasopharyngeal carcinoma (NPC) was once regarded as a mysterious regional disease, as its incidence was exceptionally high in southern China, Southeast Asia, and other regionsâparticularly in Guangdong Province, Chinaâleading to its historical designation as âGuangdongâŠ
In the field of autoimmune disease treatment, 2021 marked a significant milestoneâthe world’s first-in-class dual-target biologic drug Telitacicept (brand name: Tai AiÂź), independently developed in China, was officially approved for marketing for the treatment ofâŠ
IgA nephropathy is the most common primary glomerular disease in China, accounting for approximately 40%â50% of all primary glomerulonephritis cases. For many years, the treatment of IgA nephropathy has primarily relied on supportive therapies, especiallyâŠ
đ€ When well-defined red patches covered in silvery-white scales appear on the skin, it is often more than just a cosmetic concernâit reflects a “microscopic war” being waged on the skin’s surface. Plaque psoriasis isâŠ
đ€ In China, what is the most common primary glomerulonephritis leading to kidney failure in young and middle-aged adults? The answer is primary IgA nephropathy. đ This disease has an insidious onset, often presenting initiallyâŠ
For decades, “Made in China” in pharmaceuticals conjured images of generic drugs and manufacturing scale. Today, that narrative is obsolete. A quiet revolution is reshaping the global biotech landscape, driven by China’s emergence as aâŠ
đ« Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by persistent airflow limitation and chronic airway inflammation. đ€ Today, COPD remains a major global health challenge and continues to place a growingâŠ
Primary hypertension remains one of the most widespread chronic conditions globally. đ Currently, approximately 1.2 billion adults are affected by hypertension globally, yet only about 23% achieve blood pressure control targets (<140/90 mmHg). đ AmongâŠ
In the fast-evolving landscape of lung cancer treatment, targeted therapies have reshaped the meaning of âprecision medicine.â But long before todayâs new-generation drugs took center stage, several pioneering therapies laid the foundation for modern targetedâŠ
